Source Bioscience Share Discussion Threads

[modform] 07/9/2015 19:11

If there are that many sells and share price drops by less than 1%, there has to be a buyer in the background, I may add some more

[buywell3] 07/9/2015 16:34

7,717,596 traded

Another RNS soon

[buywell2] 05/9/2015 16:55

peter

If you read the interims you will see that SBS have just landed their first EU Next Generation DNA sequencing contract (NGS) (see end of post)

This latest development re OGT software was probably key

I am hoping that more decent EU NGS contracts will follow plus I hope to see a win from Genomics England re the 100,000 Genome Project as work ramps up.

When push comes to shove and fast , quality results are needed to meet timescales an experienced and NHS accredited company like Source BioScience can make a difference.

I would like to see them given a QC role in the project as an independent auditor of data results ... say 10% of the tests done, done again by SBS with SBS Sequencing Equipment and OGT software.

In a sort of similar role that NHS Wales uses FocalPoint to do QC checks on Cervical cancer smears.

QC is very important in such a litgation riddled area as the NHS has become and prevention of mistakes saves lives, time and monies in the long run.





Post-period events

-- Completion of the acquisition of Select Pharma Laboratories Ltd ('Select') on 17 August 2015 for up to GBP7.3 million in cash; the acquisition will provide the enlarged Group with the expertise and capability to provide stability testing and Quality Control batch testing services that are highly complementary with the Group's existing stability storage services

-- Award of our first contract with the European Centre for Disease Control, Stockholm for next generation DNA sequencing, worth up to Euro 1.2 million over three years

[peterz] 05/9/2015 09:20

Buywell - I don't usually get through your long posts but, as a really long (suffering at large loss)time holder of quite a few shares, I finished and enjoyed all of these.

OGT certainly have the ability to get good research grants - not an easy task even in good times.

Thanks for the above posts.

[buywell2] 04/9/2015 08:17

The 100,000 Genomes Project is mentioned in the posts above today

OGT received grants from the SBRI ( Small Businesses Research Initiative) to develop the NGS software that SBS has just acquired access to.

'The Small Business Research Initiative for Healthcare (SBRI Healthcare) is an NHS England initiative, championed by the Academic Health Science Networks (AHSNs), who aim to promote UK economic growth whilst addressing unmet health needs and enhancing the take up of known best practice.


(see last couple of para's at end of the following 'The Challenges'

So both the NHS and the UK Government are behind the following project .... and something in which The Source BioScience Group now has the staff, equipment and analytic software that such projects require.

One would imagine SBS now stand to benefit.




.................. 100,000 Genomes Project ....................


To bring the predicted benefits of genomics to NHS patients is why the Prime Minister launched the 100,000 Genomes Project in late 2012.

Genomics England, a company wholly owned and funded by the Department of Health,
was set up to deliver this flagship project which will sequence 100,000 whole genomes from NHS patients by 2017.

Its four main aims are; to create an ethical and transparent programme based on consent; to bring benefit to patients and set up a genomic medicine service for the NHS; to enable new scientific discovery and medical insights;and to kick start the development of a UK genomics industry.

The project will focus on patients with a rare disease and their families and patients with cancer.

The first samples for sequencing are being taken from patients living in England
with discussions taking place with Scotland, Wales and Northern Ireland about potential future involvement.

Why cancer and rare diseases?

In the UK, just fewer than 160,000 people died from cancer in 2011 with over 330,000 new cases reported every year. Because cancer is more likely to occur as people age,we expect the number of cancer cases to rise as people live longer. And although rare diseases are individually very uncommon, because there are between 5000 and 8000 of them, a surprisingly large number of people are affected in total – 3 million – or, put another way one in 17 (or between 6 and 7 percent) of the UK population.

Genomics has great potential for both because both rare disease and cancer are strongly linked to changes in the genome. Cancer begins because of changes in genes within what was a normal cell.

Although a cancer starts with the same DNA as the patient, it develops
mutations or changes which enable the tumour to grow and spread. By taking DNA from the tumour and DNA from the patient’s normal cells and comparing them, the precise changes are detected. Knowing and understanding them strongly indicates which treatments will be the most effective.

Genomics has already started to guide and inform doctors about the best treatment for individual patients.

We’ve already mentioned Herceptin for HER2 positive breast cancer but we are only at the beginning. Many more cancer types, including those for whom there is hardly any successful current treatments such as lung cancer could be helped if only we knew which gene changes were important.

At least 80 percent of rare diseases are genomic with half of new cases found in
children. Knowledge of the whole genome sequence may identify the cause of some
rare diseases and help point the way to new treatments for these devastating conditions – vital progress given that some rare diseases take two or more years just to identify.

As most rare diseases are inherited, the genomes of the affected individual (usually a child) plus two of their closest blood relatives will be included to pinpoint the cause of the condition.

In all, it is anticipated that about 75,000 people will be involved
of which 40,000 will be patients with serious illness.

Thenumbers add up like this: 50,000 genomes from cancer – two per patient, therefore 25,000 patients. 50,000 from rare disease – three per patient (affected person plus two blood relatives) – therefore roughly 17,000 patients, 33,000 others.

In all, just over 40,000 patients, and about 75,000 people involved in total.

There has already been an extraordinary response by patients and their families wanting to take part in the Genomics England pilot.

Some patients involved in the 100,000 Genomes Project have already benefitted,
because a better treatment is identified for them or their condition is diagnosed for the first time. See our news section for more details. However, for most, the benefit will be in knowing that they will be helping people like them in the future through research on the genome data they generously allow to be studied but all will know that because of their involvement, an infrastructure will be developed which, in the future will enable the NHS
to offer genomic services much more widely, to any patient who might benefit.

THE CHALLENGES

To make genomics a reality for the NHS it has to be of high quality, fast and affordable with results that are readily understood.

How can this be done?

............... The sequencing challenge ..................

Genomics England has invested in the latest, state of the art sequencing machines to sequence the 100,000 genomes in the project. This is the first time sequencing has been done on such a scale in the UK. At first, all results will be double checked using existing clinical testing. This is to ensure that the information it delivers is of such high quality that doctors are confident to use it in making major decisions about care.


...................... The data challenge ....................

The first step after sequencing is to compare the possibly millions of differences between the patient’s genome and a reference genome, a process called variant calling. The next hurdle - annotation - is to interpret the meaning and importance of those differences which are important. Some of the differences will just be natural harmless variations between individuals, but some will be damaging and almost certainly involved in the development of disease.

In truth, much of the genome is still a mystery, requiring an immense amount of work to understand.

The raw data from one genome is about 200GB which would occupy most of the
average laptop’s hard drive. Just the annotations would easily fill a DVD by themselves.

This mountain of data needs to be sifted, analysed and presented in a way that is helpful to doctors, most of whom will not have specialist knowledge of gene changes.

Genomics England is investing in the people, expertise and technology to undertake this work.

[buywell2] 04/9/2015 07:45

Re previous 4 posts

I must say SBS has moved in a very efficient manner regarding this latest acquisition from OGT

I see the collaboration element of this 'hot of the press' deal , as an extension NGS service provision of existing OGT clients to use in future SBS NGS services that will in effect provide a seemless transition regarding quality and perhaps an improved one in terms of speed and depth of service offerings.

The upshot of that is that not only will the client list of the Source BioScience Group increase due to the recent Select Pharma acquisition but now it will get even larger due to the OGT clients brought in by the 'collaboration'.

[buywell2] 04/9/2015 07:25

To all those PI's that sold out last year, but still read this thread ... despite my attempts to try to show that Institutions were taking ever greater interest in the Source BioScience Group story .... I hope this does not upset those sellers .... especially those who went into the FTSE 100 ... see above thread header chart SBS V FTSE100 ... in the mistaken belief that they would do better or they could buy back in at 10p as some said.

5 year SBS chart plotted V the FTSE 100....for those who think BIG stocks are better
'>


Re the above post ...... read on .... this seems a very good deal for SBS ... guess who uses Sanger sequencing, microarray and fluorescence in situ hybridisation (FISH).
Note:

''The software will integrate a full spectrum of genetic tests, including NGS, Sanger sequencing, microarray and fluorescence in situ hybridisation (FISH).''



OGT RECEIVES PHASE II FUNDING FOR SOFTWARE DEVELOPMENT

March 26, 2015


Oxford Gene Technology (OGT) has been awarded a £1.2m phase two Small Business Research Initiative (SBRI) Healthcare contract to develop Next Generation Sequencing (NGS) analysis software, following the successful completion of phase one and an evaluation by Genomics England, UK Department of Health and Innovate UK.

The software will integrate a full spectrum of genetic tests, including NGS, Sanger sequencing, microarray and fluorescence in situ hybridisation (FISH).

The SBRI contract is managed by Genomics England, to support the implementation of the 100,000 Genomes Project which aims to sequence 100,000 whole genomes from NHS patients by 2017. OGT was awarded £200k to develop the software in July 2014 during phase one of the initiative.

The selection process for phase two involved an assessment of potential patient impact, technological step change and a route to commercialisation. James Clough, Executive Vice President Commercial, OGT said: “The award of this £1.2m contract underlines OGT’s position as a leading developer of cutting-edge products for molecular genetics. OGT has customers in over 60 countries worldwide and will use its extensive sales and marketing infrastructure to successfully commercialise the resulting product.”

Professor Tim Hubbard, Head of Genome Analysis at Genomics England commented, “For widespread use of genome sequencing in routine health care the development of accurate and reliable interpretation software is critical. We are encouraged to see new and existing companies developing products and services in this space.” -

[buywell2] 04/9/2015 07:06

The importance in the development of new drug compounds that are now being preclinically tested due to the increased focus of the Pharma sector on new drugs that are required due to the rise of 'Personalized Medicine'; is going to correlate directly with the success of companies and CRO's that can offer the molecular diagnostic tests , DNA Sequencing , Gene expression , biomarker assays , and other Genomic services that BIG Pharma requires.

In connection with the news yesterday and the previous 2 posts

The Source BioScience Group have made no secret of their desire to be the No. 1 DNA Next Generation Sequencing service provider in the EU

The company are also starting off providing these NGS DNA services in the USA.

Increasingly BIG Pharma will not just want the data results from the tests.

It will want an analysis of that data ... to do that a software package is required that can 'fit' the data to the clients requirements.



Read on relate to above two posts


OGT awarded SBRI contract to develop innovative NGS analysis software

Monday 21 July 2014

Product types:Software Applications :Cancer research, Clinical genetics research, Cytogenetics research, Molecular genetics research

Oxford Gene Technology (OGT), the molecular genetics company, today announced it has been awarded a £200K phase one development contract by the Small Business Research Initiative (SBRI) healthcare competition.

The contract is to develop whole genome Next Generation Sequencing (NGS) analysis software to increase the accuracy, and enhance the analysis of genomic sequence data. This landmark project has the potential to accelerate the diagnosis of cancer and rare diseases, ultimately supporting patient care and research.

The SBRI is a collaboration between the UK Department of Health and Genomics England Ltd. The initiative operates a competition for funding designed to support the development of innovative technologies that address the requirements of the 100K Genome Project. This includes bioinformatics and analysis algorithms, through to the development of new commercial products for genomic screening and stratified medicine. The contracts are awarded in two phases; the first enables companies to demonstrate the technical feasibility of their product and if successful, they are eligible for a second phase of funding to develop and test the product further.

OGT has considerable experience gained in the design and development of its class-leading software for microarray and NGS data interpretation. The Company will apply this knowledge to develop a clinician-friendly interpretation package for whole genome scale genetic variant data.

Dr Mike Evans, CEO of OGT said: “The award of this contract demonstrates our position at the forefront of NGS data analysis and clinical interpretation plus our ability to rapidly commercialise a resulting product using our extensive international sales and marketing infrastructure. This software will significantly enhance the ability of clinicians to understand and make use of patient genomic data, allowing the delivery of truly personalised medicine.”

[buywell3] 03/9/2015 20:15

OGT sells its sequencing services biz to Source BioScience for an undisclosed sum

03-09-2015

Oxford Gene Technology (OGT) on Thursday said it is selling its sequencing services business to Source BioScience (LSE: SBS) for an undisclosed amount to focus on genomics products portfolio.

Source BioScience will also gain access to OGT’s analysis software as part of the deal, the company said in a statement.

The spin-off is part of the company’s restructuring plan.

[buywell3] 03/9/2015 20:09

No RNS today .... this one slid in on the quiet .... but it reads well




Source BioScience and Oxford Gene Technology Collaborate


3rd Sep 2015

Source BioScience and Oxford Gene Technology Collaborate to Deliver Market-leading Next-generation Sequencing Service


On 1st September 2015, Source BioScience (LSE: SBS), the international laboratory services and products business, acquired the next-generation sequencing services business from Oxford Gene Technology (‘OGT’).

Following a series of successful acquisitions in recent years, Source BioScience has continued to expand and increase its products and services portfolio. The transfer of business from OGT to Source BioScience is hoped to contribute to the continued success and organic growth of the Company.

Dr Nick Ash, CEO of Source BioScience commented: “We are dedicated to delivering the highest-quality service to our customers and have made significant investment in our genomics and next-generation sequencing capability over a number of years. During that period we have forged a strong relationship with OGT and worked together on a number of projects. This most recent collaboration will enable customers to benefit from cutting-edge laboratory services from Source BioScience in conjunction with OGT’s leading analysis software.”

A provider of genetics research solutions, OGT has seen significant growth in its genomics products portfolio of late, and has, therefore, refocused its strategy to fuel further growth in the products business.

Mike Evans, CEO of OGT commented: “We will be providing our genetics analysis service customers with a high calibre alternative to OGT. We have worked closely with Source BioScience, well known as a trusted provider of state-of-the-art laboratory services, to ensure our customers will continue to receive best-in-class service and support, coupled with a seamless transition. Furthermore, OGT’s analysis software will be licensed to Source BioScience as part of the transfer, allowing customers continued access to the consistent, high quality, genetic analysis that OGT provides.”

[buywell3] 01/9/2015 07:12

Richard Griffiths has sold a few .... bit disappointing that

Wonder who bought them though ?

[bigman] 30/8/2015 07:16

The half year results are very impressive, it is a rare beast that makes profits in this sector.

[buywell3] 28/8/2015 09:44

Note the moving averages now as to those in the exact same position in 2012

On any positive newsflow later this year eg Autumn update or another contract win , a SBS 20p share price will make this chart look even better than it already is

Also note how SBS is whacking the FTSE out of the park



V moving averages






V FTSE 100

[buywell2] 27/8/2015 09:01

Re the above , and taken from the interims the other day

''The Source BioScience NIPT service uses cutting-edge DNA sequencing technology to analyse foetal cell-free DNA from maternal blood for chromosomal abnormalities.''


Hence SBS are well capable of doing predictive blood tests as detailed in the article

Plus they already have the equipment and staff capable of doing them.

[buywell2] 26/8/2015 07:58

Re 10m shares yesterday expect another RNS soon

[p1nkfish] 26/8/2015 00:13

hope he's not a jinx.

[peterz] 25/8/2015 08:19

Must have something to brag about to the market with regard to our new board appointment! Much of the reading is stating previous companies that have gone into liquidation etc but nothing to do with Tim. Im sure negotiations for his skills were sensible.

[buywell2] 21/8/2015 09:20

...... In a worrying time re China , reasons to be cheerful part 1 .........





China is in trouble and further devaluations of the Yuan now seem certain with news today of the manufacturing index falling yet again.

Thus their export driven economy suffers and they are now highly likely to devalue another 5% within a month.

I think this will be followed by another 10% on top of that by early 2016 for a total devaluation of 20%.

The level they will try to get back to chartwise is around 1.46



The Yuan rose a lot in the last decade hence the Chinese slowdown , China must and will act to get its exports earning US dollars again but more importantly keep its workers employed. Otherwise unrest could follow.






How does this affect Source BioScience ?


Well luckily SBS acquired Vindon Healthcare last year and they had two operations based in the USA , one in Atlanta and one in California.

The one in California is brand new and offers considerable scope for Source Bioscience to develop it further by introducing additional SBS services.

The same goes for Atlanta with the introduction of overnight DNA Sequencing in both sites


The latest acquisition of Select Pharma JUST completed presents yet another exciting opportunity to introduce their services also into both these USA sites so that batch testing for example can be done for foreign clients so as to satisfy FDA requirements DIRECT on USA soil and as near as possible to their sales targets.


Conclusions.


1. USA turnover and hence profits look set to rise in 2016

2. The $USD is rising due to China devaluation

3. The $USD looks set to rise further in 2016 as China devalues yet again

4. Future USA based earnings from $USD strength should benefit Source BioScience

[buywell2] 20/8/2015 09:52

Re the above by buywell3 , this chart as I can do charts also. Demonstrates how a FTSE 100 Commodity stock Kazakmys (KAZ) has fared V Source BioScience (SBS) a small cap stock over the last 4 years.

I seem to remember reading about some posters wanting or believing FTSE 100 stocks were a better investment

KAZ is one of the top advfn risers today


The purple line is SBS , as you can see KAZ has some catching up to do


free stock charts from uk.advfn.com

[buywell3] 20/8/2015 08:55

KAZ half year results out today and the stock is up 20%

This is a MULTI $BILLION company with a MEGA $TURNOVER



However

I expect Source Bioscience (SBS) to beat its profit number next week

[buywell3] 19/8/2015 12:10

RNS says Henderson Global has added circa 8m shares and stands at 19.78%

They must rate SBS then .... like many others do

Interims out next wednesday is my guess

18p beckons afterwards

dyor

[peterz] 19/8/2015 11:58

Buywell -

Your word is etc

HGI.